Advances in chemotherapy for patients with extremity soft tissue sarcoma

Orthop Clin North Am. 2006 Jan;37(1):15-22. doi: 10.1016/j.ocl.2005.07.001.

Abstract

Doxorubicin-based chemotherapy does not appear to offer a survival benefit to patients who have high-risk primary extremity soft tissue sarcomas, whereas ifosfamide-based chemotherapy does. This benefit is likely histology- and size-specific. Until a less toxic targeted systemic therapy is developed, treatment with ifosfamide should be strongly considered in patients who have high-risk primary extremity soft tissue sarcomas.

Publication types

  • Comparative Study
  • Review

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Cisplatin / adverse effects
  • Cisplatin / therapeutic use
  • Disease-Free Survival
  • Dose-Response Relationship, Drug
  • Doxorubicin / adverse effects
  • Doxorubicin / therapeutic use
  • Extremities
  • Female
  • Humans
  • Ifosfamide / adverse effects
  • Ifosfamide / therapeutic use
  • Male
  • Neoadjuvant Therapy / methods*
  • Neoplasm Invasiveness / pathology*
  • Neoplasm Staging
  • Prognosis
  • Randomized Controlled Trials as Topic
  • Risk Assessment
  • Sarcoma / drug therapy*
  • Sarcoma / mortality*
  • Sarcoma / pathology
  • Sarcoma / surgery
  • Survival Analysis

Substances

  • Doxorubicin
  • Cisplatin
  • Ifosfamide